Effectiveness of Meropenem-Levofloxacin with Meropenem-Amikasin Towards LOS & Leukocytes to RASPRO III Stratification Community Pneumonia Patients

Authors

  • Hadi Sumarsono Universitas Pancasila
  • Dian Ratih Laksmitawati Universitas Pancasila ,
  • Ronald Irwanto Universitas Pancasila ,

DOI:

https://doi.org/10.35814/jifi.v18i2.880

Keywords:

Community pneumonia, meropenem, levofloxacin, amikasin, LOS, decreased leukocytes

Abstract

Administration of antibiotics in the private hospital "X" adopted a concept called Ronald
Irwanto Antimicrobial Steweardship Program (RASPRO). The suggestion of an empirical antibiotic
combination in type III stratifi cation community pneumonia patients was meropenem-levofl oxacin
or meropenem-amikasin. The aim of the study was to determine the eff ect of empirical antibiotic
combination meropenem-levofl oxacin with meropenem-amikacin to RASPRO type III stratifi cation
community pneumonia patients towards the LOS and decreased leukocytes. The test sample calculated
using diff erence between two population proportions formula and analysed using Chi-square method.
Diabetes mellitus, immobilisation and geriatrics as confounding variables were controlled by logistic
regretion multivariate analysis. The results showed that meropenem-levofl oxacin had a tendency 1.81
times to experience LOS < 5 days and 0.92 times to experience decreased leukocytes ≥ 10% compared
to meropenem-amikacin, but both were not signifi cant (p 0.161 and p 0.835). The result control of
confounding variables were found that geriatrics as a meaningful confounding variable eff ect of LOS
and no confounding variables were considered to aff ect the decreased leukocytes. In conclusion, there
is no eff ect of empirical antibiotic combination meropenem-levofl oxacin with meropenem-amikacin
towards the LOS and decreased leukocytes to RASPRO type III stratifi cation community pneumonia
patients using statistics after controlling the confounding variables.

References

Downloads

Published

2020-10-28

Issue

Vol. 18 No. 2 (2020): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.